Literature DB >> 26900287

Inflammation in irritable bowel syndrome: Myth or new treatment target?

Emanuele Sinagra1, Giancarlo Pompei1, Giovanni Tomasello1, Francesco Cappello1, Gaetano Cristian Morreale1, Georgios Amvrosiadis1, Francesca Rossi1, Attilio Ignazio Lo Monte1, Aroldo Gabriele Rizzo1, Dario Raimondo1.   

Abstract

Low-grade intestinal inflammation plays a key role in the pathophysiology of irritable bowel syndrome (IBS), and this role is likely to be multifactorial. The aim of this review was to summarize the evidence on the spectrum of mucosal inflammation in IBS, highlighting the relationship of this inflammation to the pathophysiology of IBS and its connection to clinical practice. We carried out a bibliographic search in Medline and the Cochrane Library for the period of January 1966 to December 2014, focusing on publications describing an interaction between inflammation and IBS. Several evidences demonstrate microscopic and molecular abnormalities in IBS patients. Understanding the mechanisms underlying low-grade inflammation in IBS may help to design clinical trials to test the efficacy and safety of drugs that target this pathophysiologic mechanism.

Entities:  

Keywords:  Inflammation; Irritable bowel syndrome; Mast cells; Neuroendocrine cells; Pathology

Mesh:

Substances:

Year:  2016        PMID: 26900287      PMCID: PMC4734999          DOI: 10.3748/wjg.v22.i7.2242

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  207 in total

1.  Abnormal intestinal motility in irritable bowel syndrome.

Authors:  T Schmidt; A Pfeiffer; H Kaess
Journal:  Gastroenterology       Date:  1996-11       Impact factor: 22.682

2.  Several receptors mediate the antisecretory effect of peptide YY, neuropeptide Y, and pancreatic polypeptide on VIP-induced fluid secretion in the rat jejunum in vivo.

Authors:  A Souli; J Chariot; T Voisin; O Presset; A Tsocas; A Balasubramaniam; M Laburthe; C Rozé
Journal:  Peptides       Date:  1997       Impact factor: 3.750

Review 3.  Colonic myoelectric activity in the irritable bowel syndrome.

Authors:  W J Snape; G M Carlson; S Cohen
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

4.  Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre.

Authors:  R Sadik; P-O Stotzer; M Simrén; H Abrahamsson
Journal:  Neurogastroenterol Motil       Date:  2007-11-05       Impact factor: 3.598

5.  Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.

Authors:  Cesare Cremon; Luciana Gargano; Antonio M Morselli-Labate; Donatella Santini; Rosanna F Cogliandro; Roberto De Giorgio; Vincenzo Stanghellini; Roberto Corinaldesi; Giovanni Barbara
Journal:  Am J Gastroenterol       Date:  2009-01-13       Impact factor: 10.864

6.  Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.

Authors:  L-H Wang; X-C Fang; G-Z Pan
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 7.  A role for inflammation in irritable bowel syndrome?

Authors:  G Barbara; R De Giorgio; V Stanghellini; C Cremon; R Corinaldesi
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

8.  The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors.

Authors:  Kwang Jae Lee; Yeong Bae Kim; Jang Hee Kim; Hoek Chun Kwon; Dong Kyu Kim; Sung Won Cho
Journal:  J Gastroenterol Hepatol       Date:  2008-11       Impact factor: 4.029

Review 9.  Irritable bowel syndrome: emerging paradigm in pathophysiology.

Authors:  Yoo Jin Lee; Kyung Sik Park
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

10.  Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome.

Authors:  J Steens; P J Van Der Schaar; C Penning; J Brussee; A A M Masclee
Journal:  Neurogastroenterol Motil       Date:  2002-06       Impact factor: 3.598

View more
  27 in total

Review 1.  New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.

Authors:  Emanuele Sinagra; Gaetano Cristian Morreale; Ghazaleh Mohammadian; Giorgio Fusco; Valentina Guarnotta; Giovanni Tomasello; Francesco Cappello; Francesca Rossi; Georgios Amvrosiadis; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

2.  Metabolomics reveals elevated urinary excretion of collagen degradation and epithelial cell turnover products in irritable bowel syndrome patients.

Authors:  Mai Yamamoto; Maria Ines Pinto-Sanchez; Premysl Bercik; Philip Britz-McKibbin
Journal:  Metabolomics       Date:  2019-05-20       Impact factor: 4.290

3.  Evaluation of the effect of 1,3-bis-(4-phenyl-[1,2,3] triazole-1-il)2-propanol in comparison with metronidazole in an in vitro culture of Blastocystis in samples of patients with irritable bowel syndrome.

Authors:  L García-Flores; J G Santillán-Benítez; E Cuevas-Yáñez; P Caballero-Vásquez; S Zamudio-Chávez; E Morales-Ávila
Journal:  J Parasit Dis       Date:  2019-05-02

Review 4.  Natural polyphenols for the prevention of irritable bowel syndrome: molecular mechanisms and targets; a comprehensive review.

Authors:  Nazanin Momeni Roudsari; Naser-Aldin Lashgari; Saeideh Momtaz; Mohammad Hosein Farzaei; André M Marques; Amir Hossein Abdolghaffari
Journal:  Daru       Date:  2019-07-04       Impact factor: 3.117

5.  Elevated serum neopterin levels in children with functional constipation: association with systemic proinflammatory cytokines.

Authors:  Ceren Cıralı; Emel Ulusoy; Tuncay Kume; Nur Arslan
Journal:  World J Pediatr       Date:  2018-03-16       Impact factor: 2.764

6.  Serum resolvin D1 levels as a marker of inflammation in constipation dominant irritable bowel syndrome.

Authors:  Eylem Karatay; Özlem Gül Utku
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

Review 7.  Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?

Authors:  Hiroshi Fukui
Journal:  Inflamm Intest Dis       Date:  2016-07-20

8.  Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing.

Authors:  Anne-Claire B van Orten-Luiten; Nicole M de Roos; Soumia Majait; Ben J M Witteman; Renger F Witkamp
Journal:  Cannabis Cannabinoid Res       Date:  2021-02-11

9.  Patients with functional bowel disorder have disaccharidase deficiency: A single-center study from Russia.

Authors:  Saria Dbar; Olga Akhmadullina; Elena Sabelnikova; Nikolai Belostotskiy; Asfold Parfenov; Svetlana Bykova; Sergey Bakharev; Elena Baulo; Alexandra Babanova; Lilia Indeykina; Tatyana Kuzmina; Tatiana Kosacheva; Aleksey Spasenov; Alina Makarova
Journal:  World J Clin Cases       Date:  2021-06-16       Impact factor: 1.337

10.  "Association between dietary inflammatory index (DII) and risk of irritable bowel syndrome: a case-control study".

Authors:  Elham Eslampour; Koroush Ghanadi; Vahideh Aghamohammadi; Alireza Moayed Kazemi; Rasool Mohammadi; Farhad Vahid; Amir Abbasnezhad
Journal:  Nutr J       Date:  2021-06-28       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.